WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GYRE stock forecasts and price targets.

Forecast return on equity

Is GYRE forecast to generate an efficient return?

Company
428.74%
Industry
153.19%
Market
81.87%
GYRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GYRE forecast to generate an efficient return on assets?

Company
216.48%
Industry
36.07%
GYRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GYRE earnings per share forecast

What is GYRE's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.42+200%
Avg 2 year Forecast
$1.17+735.71%
Avg 3 year Forecast
$1.72+1,128.57%
GYRE's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GYRE revenue forecast

What is GYRE's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$136.7M+29.26%
Avg 2 year Forecast
$238.0M+125.04%
Avg 3 year Forecast
$356.3M+236.86%
GYRE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GYRE earnings growth forecast

How is GYRE forecast to perform vs Biotechnology companies and vs the US market?

Company
132.23%
Industry
13.28%
Market
18.17%
GYRE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GYRE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GYRE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GYRE revenue growth forecast

How is GYRE forecast to perform vs Biotechnology companies and vs the US market?

Company
49.51%
Industry
65.48%
Market
10.37%
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GYRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GYRE$8.40N/AN/A
PHVS$14.50$55.00+279.31%Buy
OCS$18.12$33.67+85.80%Strong Buy
ELVN$16.22$39.25+141.99%Strong Buy
CMRX$8.54$8.51-0.32%Buy
View Top Biotech Stocks

Gyre Therapeutics Stock Forecast FAQ

What is GYRE's earnings growth forecast for 2025-2027?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual earnings growth rate of 132.23% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and it is also forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Gyre Therapeutics's earnings in 2025 is $12,085,000.On average, 1 Wall Street analyst forecast GYRE's earnings for 2025 to be $39,317,226, with the lowest GYRE earnings forecast at $39,317,226, and the highest GYRE earnings forecast at $39,317,226. On average, 1 Wall Street analyst forecast GYRE's earnings for 2026 to be $109,526,557, with the lowest GYRE earnings forecast at $109,526,557, and the highest GYRE earnings forecast at $109,526,557.

In 2027, GYRE is forecast to generate $161,013,400 in earnings, with the lowest earnings forecast at $161,013,400 and the highest earnings forecast at $161,013,400.

If you're new to stock investing, here's how to buy Gyre Therapeutics stock.

What is GYRE's revenue growth forecast for 2025-2027?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual revenue growth rate of 49.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Gyre Therapeutics's revenue in 2025 is $105,757,000.On average, 1 Wall Street analysts forecast GYRE's revenue for 2025 to be $12,796,820,821, with the lowest GYRE revenue forecast at $12,796,820,821, and the highest GYRE revenue forecast at $12,796,820,821. On average, 1 Wall Street analysts forecast GYRE's revenue for 2026 to be $22,279,761,196, with the lowest GYRE revenue forecast at $22,279,761,196, and the highest GYRE revenue forecast at $22,279,761,196.

In 2027, GYRE is forecast to generate $33,349,432,463 in revenue, with the lowest revenue forecast at $33,349,432,463 and the highest revenue forecast at $33,349,432,463.

What is GYRE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GYRE) forecast ROA is 216.48%, which is higher than the forecast US Biotechnology industry average of 36.07%.

What is GYRE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GYRE) Gyre Therapeutics's current Earnings Per Share (EPS) is $0.14. On average, analysts forecast that GYRE's EPS will be $0.42 for 2025, with the lowest EPS forecast at $0.42, and the highest EPS forecast at $0.42. On average, analysts forecast that GYRE's EPS will be $1.17 for 2026, with the lowest EPS forecast at $1.17, and the highest EPS forecast at $1.17. In 2027, GYRE's EPS is forecast to hit $1.72 (min: $1.72, max: $1.72).

What is GYRE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GYRE) forecast ROE is 428.74%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.